
Antidepressant Comparison Tool
Compare Your Treatment Options
Select antidepressants to compare based on your symptoms, side effect tolerance, and other personal factors. This tool uses the same criteria as the article to help you understand the trade-offs between different medications.
Treatment Comparison Results
Efficacy
How well it reduces symptoms
Onset
How quickly you'll notice improvement
Side Effects
Common side effects
Special Considerations
Unique factors to consider
Personalized Recommendation
When you or a loved one need relief from obsessive‑compulsive disorder (OCD) or depression, the first question is often - which pill works best? Clofranil (clomipramine) has been a go‑to for OCD for decades, but newer drugs promise fewer side effects and easier dosing. This guide lines up Clofranil side‑by‑side with the most common alternatives so you can see the trade‑offs in plain English.
What is Clofranil (Clomipramine)?
Clofranil is a tricyclic antidepressant (TCA) whose active ingredient is clomipramine. It works by blocking the re‑uptake of serotonin and norepinephrine, increasing their levels in the brain. Originally approved for major depressive disorder, it gained a reputation for OCD because it reduces compulsive thoughts faster than many SSRIs.
Typical adult dosing starts at 25mg daily, gradually rising to 200mg depending on response and tolerance. Because it belongs to the TCA class, Clofranil can cause anticholinergic effects (dry mouth, constipation) and may require an ECG before you start, especially if you have heart disease.
How Do We Compare Antidepressants?
Before jumping into the table, here are the five criteria most patients and clinicians weigh:
- Efficacy for the target condition - does the drug lift mood or curb obsessions?
- Onset of action - how many weeks before you notice change?
- Side‑effect profile - which unwanted effects are likely?
- Drug‑food interactions - do you need to avoid meals or caffeine?
- Cost and insurance coverage - will it fit your budget?
Each alternative stacks up differently on these points, so the "best" choice depends on your personal health picture.

Side‑by‑Side Comparison
Medication | Drug Class | Primary Indication | Typical Dose | Onset (weeks) | Common Side Effects | Weight Gain | Sexual Dysfunction | Food/Drug Interactions |
---|---|---|---|---|---|---|---|---|
Clofranil | Tricyclic (TCA) | OCD, Depression | 25-200mg/day | 2-4 | Dry mouth, constipation, dizziness | Low | Moderate | Avoid CYP2D6 inhibitors; monitor with meals high in tyramine |
Fluoxetine | SSRI | Depression, OCD, Bulimia | 20-80mg/day | 4-6 | Insomnia, nausea, anxiety | Low | High | Potent CYP2D6 inhibitor; may raise levels of some antipsychotics |
Sertraline | SSRI | Depression, OCD, PTSD | 50-200mg/day | 4-6 | Diarrhea, tremor, fatigue | Low | High | Few food interactions; watch for serotonin syndrome with other serotonergics |
Paroxetine | SSRI | Depression, OCD, Anxiety | 20-60mg/day | 4-6 | Drowsiness, weight gain, withdrawal | Moderate | Very High | Strong CYP2D6 inhibitor; interacts with many meds |
Venlafaxine | SNRI | Depression, Anxiety, Panic | 75-225mg/day | 2-4 | Hypertension, nausea, insomnia | Low | Moderate | May raise blood pressure; avoid MAOIs |
Duloxetine | SNRI | Depression, Fibromyalgia, Neuropathic pain | 30-120mg/day | 4-6 | Dry mouth, constipation, liver enzyme rise | Low | Moderate | Avoid alcohol; watch liver function |
Amitriptyline | Tricyclic (TCA) | Depression, Neuropathic pain | 25-150mg/day | 2-4 | Sedation, weight gain, orthostatic hypotension | High | Low | Strong anticholinergic; must avoid alcohol and TCAs together |
Nortriptyline | Tricyclic (TCA) | Depression, Chronic pain | 25-150mg/day | 2-4 | Drowsiness, dry mouth, cardiac arrhythmia risk | Moderate | Low | Less anticholinergic than amitriptyline; still needs ECG monitoring |
Who Should Choose Clofranil?
If you have moderate‑to‑severe OCD and haven’t responded to first‑line SSRIs, Clofranil often tops the list. Its dual‑action on serotonin and norepinephrine gives it extra punch for intrusive thoughts. Patients without cardiac disease, who can tolerate occasional dry mouth and don’t mind a few dose adjustments, tend to do well.
On the flip side, people with a history of heart rhythm problems, glaucoma, or who are on multiple CYP2D6‑inhibiting drugs may want to steer clear. In those cases, a newer SSRI or SNRI can provide a smoother side‑effect profile, even if the OCD relief takes a week longer.
When Alternatives Might Be a Better Fit
- First‑line OCD treatment: Start with an SSRI like fluoxetine or sertraline, especially if you’re sensitive to anticholinergic effects.
- Depression with weight‑gain concerns: Venlafaxine or duloxetine often cause less appetite increase than TCAs.
- Elderly patients: Avoid high‑dose TCAs because of fall risk; sertraline or duloxetine are safer.
- Patients on many medicines: Choose drugs with fewer CYP interactions, such as sertraline, which has a relatively clean profile.
- Those who need pain relief: Amitriptyline or duloxetine can kill two birds with one stone - mood boost plus neuropathic pain control.

Safety Checks and Monitoring
Because Clofranil belongs to the TCA family, doctors often order a baseline ECG and repeat it after a few weeks of therapy. Blood levels aren’t routinely measured, but if you’re elderly or have liver disease, dose adjustments are key.
All antidepressants can trigger a rare serotonin syndrome when mixed with other serotonergic agents (e.g., certain migraine meds). Watch for agitation, fever, rapid heart rate, and seek help immediately.
Switching Between Medications
- Talk to your prescriber about a taper plan - abrupt stops increase relapse risk.
- If moving from a TCA to an SSRI, consider a one‑week washout to reduce serotonin overload.
- Monitor side effects closely for the first two weeks; keep a symptom diary.
- Schedule a follow‑up visit to review efficacy and adjust dosage.
Most patients feel noticeable improvement within 4‑6 weeks, regardless of the drug class, but anxiety‑related symptoms (like OCD) may lighten sooner with clomipramine.
Frequently Asked Questions
Is Clofranil safe for long‑term use?
Yes, many patients stay on it for years if it controls their OCD or depression and side effects stay manageable. Regular cardiac check‑ups are recommended, especially after dose changes.
Can I take Clofranil with alcohol?
It’s best to avoid alcohol. Mixing the two can increase sedation, worsen dizziness, and heighten heart rhythm issues.
How does Clofranil compare to sertraline for OCD?
Clinical trials show clomipramine often yields a larger reduction in Yale‑Brown Obsessive Compulsive Scale scores, but sertraline has fewer anticholinergic side effects. Many clinicians start with sertraline and switch to clomipramine if the response is inadequate.
What should I do if I miss a dose of Clofranil?
Take the missed tablet as soon as you remember, unless it’s almost time for the next dose. In that case, skip the missed one and continue with your regular schedule - don’t double up.
Are there natural alternatives to Clofranil for OCD?
Cognitive‑behavioral therapy (especially exposure and response prevention) is the only non‑pharmacologic approach with solid evidence. Some people add omega‑3 supplements, but they shouldn’t replace prescribed medication without a doctor’s OK.
Comments
The comparative table presented in the article provides a commendable overview of pharmacodynamic and pharmacokinetic properties across the selected agents.
The dual reuptake inhibition of serotonin and norepinephrine justifies Clofranil’s superior efficacy scores in obsessive‑compulsive disorder relative to the SSRIs listed.
However, the author neglects to quantify the risk of QT prolongation, a clinically salient concern for tricyclics in patients with underlying cardiac pathology.
Moreover, the side‑effect prevalence percentages are derived from heterogeneous study populations, which undermines direct head‑to‑head interpretation.
The onset metric, expressed in weeks, fails to differentiate between acute anxiolytic relief and chronic mood stabilization.
In contrast, venlafaxine’s rapid onset is appropriately contextualized with its norepinephrine surge, yet the article omits its dose‑dependent hypertensive potential.
The cost analysis is conspicuously absent, despite insurance formularies often dictating the feasibility of clomipramine versus generic SSRIs.
From a metabolic standpoint, the CYP2D6 inhibition profile of Clofranil presents a substantial drug‑interaction hazard, especially in polypharmacy regimes common among OCD patients.
The author’s recommendation to reserve Clofranil for treatment‑resistant cases aligns with clinical guidelines, but the rationale is insufficiently substantiated.
Additionally, the table overlooks the impact of patient age on tolerability, an omission that could mislead prescribers treating geriatric cohorts.
The discussion of anticholinergic burden is brief, ignoring the cumulative effect when combined with antihistamines or antipsychotics.
It is also noteworthy that the article does not address the potential for weight gain associated with paroxetine, an adverse effect that may sway patient preference.
While the language is accessible, the reliance on categorical descriptors such as “high” or “moderate” without confidence intervals reduces scientific rigor.
The inclusion of newer agents such as vilazodone or vortioxetine would have provided a more comprehensive landscape.
Finally, the recommendation engine embedded in the tool lacks transparency regarding the weighting algorithm applied to each criterion.
Overall, the piece serves as a useful primer but requires deeper quantitative analysis before it can be employed as a definitive prescribing aid.